NanoMed Pharmaceuticals, Inc., an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases. Under an Inter-institutional Agreement with The Ohio State University, the University of Kentucky Research Foundation has granted the company an option for an exclusive license to a novel Bioadhesive Berry Gel for the chemoprevention and treatment of oral epithelial dysplasia -- the precancerous lesions that develop into oral squamous cell carcinoma (SCC)
